Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled date : 2022 - 03 - 20 crawled time : 00:20 save search
Combining Microbubbles & Cell Sorting for Quick & Efficient Cell Isolation
Published: 2022-03-19 (Crawled : 00:20) - thermogenesis.com
THMO | $0.6695 3.0% 2.91% 8.6K
|
Health Technology
| Email alert
Add to watchlist
cel
Thermogenesis Holdings CEO, Dr. Chris Xu, featured in BioPharm International Q&A Article
Published: 2022-03-19 (Crawled : 00:20) - thermogenesis.com
THMO | $0.6695 3.0% 2.91% 8.6K
|
Health Technology
| Email alert
Add to watchlist
ceo international tiona
Egg freezing, IVF and surrogacy: Fertility benefits have evolved to become the ultimate workplace perk
Published: 2022-03-19 (Crawled : 00:20) - progyny.com
PGNY | $32.68 2.51% 2.45% 1.1M
|
Commercial Services
| Email alert
Add to watchlist
work
The Great Resignation is here: How to cultivate loyalty with family-focused benefits
Published: 2022-03-19 (Crawled : 00:20) - progyny.com
PGNY | $32.68 2.51% 2.45% 1.1M
|
Commercial Services
| Email alert
Add to watchlist
MIRASOL: A Randomized, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine vs Investigator’s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor Alpha Expression
Published: 2022-03-19 (Crawled : 00:20) - immunogen.com
IMGN | $31.23 0.03% 49M
|
Health Technology
| Email alert
Add to watchlist
label one therapy cancer mirvetuximab phase 3
PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent, Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor Alpha Expression
Published: 2022-03-19 (Crawled : 00:20) - immunogen.com
IMGN | $31.23 0.03% 49M
|
Health Technology
| Email alert
Add to watchlist
phase 2 one cancer mirvetuximab
Mirvetuximab Soravtansine, a Folate Receptor Alpha Targeting Antibody-Drug Conjugate, in Combination with Bevacizumab in Patients with Platinum-Agnostic Ovarian Cancer: Final Analysis
Published: 2022-03-19 (Crawled : 00:20) - immunogen.com
IMGN | $31.23 0.03% 49M
|
Health Technology
| Email alert
Add to watchlist
drug ovarian cancer cancer mirvetuximab antibody
Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study
Published: 2022-03-19 (Crawled : 00:20) - immunogen.com
IMGN | $31.23 0.03% 49M
|
Health Technology
| Email alert
Add to watchlist
ovarian cancer results cancer mirvetuximab
DEADLINE: Grab Holdings Limited f/k/a Altimeter Growth Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GRAB; GRABW
Published: 2022-03-19 (Crawled : 00:20) - prnewswire.com
GRAB | $3.36 -0.89% -0.89% 18M
|
n/a
| Email alert
Add to watchlist
growth deadline
DEADLINE: Celsius Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - CELH
Published: 2022-03-19 (Crawled : 00:20) - prnewswire.com
CELH | $68.84 -1.62% -1.64% 3.5M
|
Consumer Non-Durables
| Email alert
Add to watchlist
cel deadline
DEADLINE APPROACHING: Investors in Telefonaktiebolaget LM Ericsson with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ERIC
Published: 2022-03-19 (Crawled : 00:20) - prnewswire.com
ERIC | News | $5.1 0.79% 0.78% 19M
|
Electronic Technology
| Email alert
Add to watchlist
deadline
Core One Labs to Investigate Soliciting Investment and Potential Takeover Opportunities
Published: 2022-03-19 (Crawled : 00:20) - globenewswire.com
CLABF | $0.17 115.0% 440
|
Process Industries
| Email alert
Add to watchlist
one potential
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.